Frontiers of Medicine >

2016 , Vol. 10 >Issue 1: 52 - 60

DOI: https://doi.org/10.1007/s11684-016-0433-3

RESEARCH ARTICLE

Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma

  • Zhi Xu , 1 ,
  • Chunxiang Cao 1 ,
  • Haiyan Xia 1 ,
  • Shujing Shi 1 ,
  • Lingzhi Hong 1 ,
  • Xiaowei Wei 1 ,
  • Dongying Gu 1 ,
  • Jianmin Bian 2 ,
  • Zijun Liu 2 ,
  • Wenbin Huang 3 ,
  • Yixin Zhang 4 ,
  • Song He 5 ,
  • Nikki Pui-Yue Lee 6 ,
  • Jinfei Chen , 1
Expand
  • 1. Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
  • 2. Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
  • 3. Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
  • 4. Department of General Surgery, Nantong Tumor Hospital, Nantong 226361, China
  • 5. Department of Pathology, Nantong Tumor Hospital, Nantong 226361, China
  • 6. Department of Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Received date: 01 May 2015

Accepted date: 10 Dec 2015

Published date: 31 Mar 2016

Copyright

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg
Fold

Abstract

Hepatocellular carcinoma (HCC) is a lethal liver malignancy worldwide. In this study, we reported that protein phosphatase magnesium-dependent 1δ (PPM1D) was highly expressed in the majority of HCC cases (approximately 59%) and significantly associated with high serum α-fetoprotein (AFP) level (P= 0.044). Kaplan-Meier and Cox regression data indicated that PPM1D overexpression was an independent predictor of HCC-specific overall survival (HR, 2.799; 95% CI, 1.346–5.818, P = 0.006). Overexpressing PPM1D promoted cell viability and invasion, whereas RNA interference-mediated knockdown of PPM1D inhibited proliferation, invasion, and migration of cultured HCC cells. In addition, PPM1D suppression by small interfering RNA decreased the tumorigenicity of HCC cells in vivo. Overall, results suggest that PPM1D is a potential prognostic marker and therapeutic target for HCC.

Key words： PPM1D; hepatocellular carcinoma; prognosis; target therapy

Cite this article

Zhi Xu , Chunxiang Cao , Haiyan Xia , Shujing Shi , Lingzhi Hong , Xiaowei Wei , Dongying Gu , Jianmin Bian , Zijun Liu , Wenbin Huang , Yixin Zhang , Song He , Nikki Pui-Yue Lee , Jinfei Chen . Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Frontiers of Medicine, 2016 , 10(1) : 52 -60 . DOI: 10.1007/s11684-016-0433-3

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (Nos. 81000880 and 81370057 to Zhi Xu), the Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health (JQX12007 to Zhi Xu), the clinical special project for Natural Science Foundation of Jiangsu Province (BL2012016 to Jinfei Chen), and the Nanjing 12th Five-Year Key Scientific Project of Medicine to Jinfei Chen.

Compliance with ethics guidelines

Zhi Xu, Chunxiang Cao, Haiyan Xia, Shujing Shi, Lingzhi Hong, Xiaowei Wei, Dongying Gu, Jianmin Bian, Zijun Liu, Wenbin Huang, Yixin Zhang, Song He, Nikki Pui-Yue Lee, and Jinfei Chen declare that they have no conflict of interest. The study was approved by the institutional review board of Nantong Tumor Hospital and Nanjing Medical University (Nanjing, China). Enrolled patients provided signed informed consents on using the collected specimens for medical research.
Electronic Supplementary MaterialƒSupplementary material is available in the online version of this article at http://dx.doi.org/10.1007/s11684-016-0433-3 and is accessible for authorized users.

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87–108

DOI PMID

2
Giannelli G, Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol 2006; 40(9): 842–846

DOI PMID

3
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379(9822): 1245–1255

DOI PMID

4
Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O’Connor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94(12): 6048–6053

DOI PMID

5
Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002; 31(2): 133–134

DOI PMID

6
Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31(2): 210–215

DOI PMID

7
Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9(6): 1995–2004

PMID

8
Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, Ohki M, Inazawa J, Hirohashi S. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007; 98(3): 392–400

DOI PMID

9
Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63(8): 1876–1883

PMID

10
Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, Kim JY. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 2008; 86(3): 245–256

DOI PMID

11
Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 2006; 95(3): 257–263

DOI PMID

12
Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, Korshunov A, Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005; 23(34): 8853–8862

DOI PMID

13
Peng TS, He YH, Nie T, Hu XD, Lu HY, Yi J, Shuai YF, Luo M. PPM1D is a prognostic marker and therapeutic target in colorectal cancer. Exp Ther Med 2014; 8(2): 430–434

PMID

14
Ma D, Zhang CJ, Chen ZL, Yang H. Prognostic value of PPM1D in 800 gastric cancer patients. Mol Med Rep 2014; 10(1): 191–194

PMID

15
Yang H, Gao XY, Li P, Jiang TS. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer. Tumour Biol 2015; 36(3): 2179–2184

DOI PMID

16
Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ, Liu J. Protein phosphatase magnesium-dependent 1d (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PLoS ONE 2013; 8(3): e60775

DOI PMID

17
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011; 30(10): 1229–1240

DOI PMID

18
Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009; 50(5): 1453–1463

DOI PMID

19
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115(19): 4576–4585

DOI PMID

20
Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, Ye L, Zhang X. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 2012; 56(6): 2051–2059

DOI PMID

21
Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008; 27(2): 123–135

DOI PMID

22
Lowe J, Cha H, Lee MO, Mazur SJ, Appella E, Fornace AJ Jr. Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci (Landmark Ed) 2012; 17(1): 1480–1498

DOI PMID

23
Pärssinen J, Alarmo EL, Karhu R, Kallioniemi A. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet Cytogenet 2008; 182(1): 33–39

DOI PMID

24
Wang P, Rao J, Yang H, Zhao H, Yang L. PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells. J Huazhong Univ Sci Technolog Med Sci 2011; 31(1): 94–99

DOI PMID

25
Yin H, Yan Z, Liang Y, Liu B, Su Q. Knockdown of protein phosphatase magnesium-dependent 1 (PPM1D) through lentivirus-mediated RNA silencing inhibits colorectal carcinoma cell proliferation. Technol Cancer Res Treat 2013; 12(6): 537–543

PMID

26
Wang W, Zhu H, Zhang H, Zhang L, Ding Q, Jiang H. Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells. Braz J Med Biol Res 2014; 47(12): 1044–1049

DOI PMID

27
Zhang C, Chen Y, Wang M, Chen X, Li Y, Song E, Liu X, Kim S, Peng H. PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells. World J Surg Oncol 2014; 12(1): 258

DOI PMID

28
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88(3): 323–331

DOI PMID

29
Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G, Choi J. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 2007; 101(3): 269–278

DOI PMID

Options
Outlines

/

〈 〉